|
Friday, December 8, 2023, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET)
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Chronic Lymphocytic Leukemia (Part 3 of a 4-Part Series)A CME Friday Satellite Symposium and Virtual Event Preceding the 65th ASH Annual Meeting
Location
Omni San Diego Hotel 675 L Street San Diego, CA 92101 Phone: (619) 231-6664 Program Schedule — Pacific Time 2:45 PM – 3:15 PM — Registration and Light Snacks 3:15 PM – 5:15 PM — Educational Meeting Meeting Room Grand Ballroom (Level 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Farrukh T Awan, MD Professor of Internal Medicine Director of Lymphoid Malignancies Program Harold C Simmons Comprehensive Cancer Center The University of Texas Southwestern Medical Center Dallas, Texas Matthew S Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Stephen J Schuster, MD Director, Lymphoma Program and Lymphoma Translational Research Robert and Margarita Louis-Dreyfus Professor in CLL and Lymphoma Professor of Medicine, Hematology/Oncology University of Pennsylvania School of Medicine Philadelphia, Pennsylvania William G Wierda, MD, PhD Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey Section Chief, Chronic Lymphocytic Leukemia Center Medical Director Department of Leukemia Division of Cancer Medicine Executive Medical Director Inpatient Medical Services The University of Texas MD Anderson Cancer Center Houston, Texas Jennifer Woyach, MD Professor Division of Hematology Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus, Ohio Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly.
Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks 3:15 PM – 5:15 PM — Educational Meeting MODULE 1: Front-Line Treatment for Chronic Lymphocytic Leukemia (CLL) — Dr Wierda
MODULE 2: Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in the Treatment of CLL — Dr Davids
MODULE 3: Optimal Management of Adverse Events (AEs) with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Awan
MODULE 4: Selection and Sequencing of Therapies for R/R CLL — Dr Woyach
MODULE 5: Promising Investigational Agents and Strategies — Dr Schuster
Target Audience
CME Credit Form Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene Corporation, Cellectar Biosciences Inc, DAVA Oncology, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Verastem Inc; Contracted Research: Pharmacyclics LLC, an AbbVie Company. Dr Davids — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Novartis, Nuvalent; Contracted Research (Investigator on the Grant): Novartis and Ascentage Pharma (grants manager to Dr Davids: Roberto Avalos, DFCI); Nonrelevant Financial Relationship: German CLL Study Group (CLL17 safety monitoring board chair), UpToDate (authorship royalties). Dr Schuster — Advisory Committee: Caribou Biosciences Inc, Genentech, a member of the Roche Group, Nordic Nanovector, Novartis, viTToria Biotherapeutics Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Caribou Biosciences Inc, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, MorphoSys, Mustang Bio, Novartis; Contracted Research: AbbVie Inc, Bristol Myers Squibb, DTRMBiopharma Co Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Juno Therapeutics, a Celgene Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis; Data and Safety Monitoring Board/Committee: Fate Therapeutics; Inventor on Patent: “Combination therapies of chimeric antigen receptors and PD-1 inhibitors,” Owned by Penn and licensed by Novartis. Dr Wierda — Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Accutar Biotechnology Inc, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Numab Therapeutics AG, Nurix Therapeutics Inc — Supported by the NIH/NCI under award number P30 CA016672 and using MDACC Cancer Center Support Grant (CCSG) shared resources, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL). Dr Woyach — Advisory Committee and Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Newave Pharmaceutical Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly. Omni San Diego Hotel
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.
There is no fee to participate in this hybrid event. For the in-person symposium in San Diego preregistration is required as seating is limited. NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians» IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |